Back to Results
First PageMeta Content
Melanoma / Organochlorides / Organofluorides / Vemurafenib / BRAF / Raf kinase / Cancer / Skin cancer / Protein kinase inhibitor / Medicine / Oncology / Oncogenes


Microsoft Word - Consultation DAP_1207_BRAF V600 _GSK2118436_.doc
Add to Reading List

Document Date: 2014-11-06 23:50:13

Open Document

File Size: 826,53 KB

Share Result on Facebook

Company

Roche Diagnostics Australia Pty Ltd / GlaxoSmithKline Australia / Australia Pty Ltd / Molecular Pathology Frome Rd SA / /

Country

Australia / /

Event

FDA Phase / /

Facility

The laboratory / Hunter Area Pathology Service John Hunter Hospital / University of Adelaide / /

IndustryTerm

healthcare resources / decision analytical protocol / /

MedicalCondition

cancer / disease / congenital disorders / metastasis / skin cancer / IV melanoma / tumour / melanomas / infectious / melanoma / infectious disease / metastatic melanoma / /

MedicalTreatment

bypass / /

Organization

University of Adelaide / School of Population Health and Clinical Practice / Therapeutic Goods Administration / Australian government / Department of Neuropathology Royal Prince Alfred Hospital NSW / Hunter Area Pathology Service John Hunter Hospital / Department of Health / Medical Services Advisory Committee / Peter MacCallum Centre / Medicare / /

Position

Commonwealth Minister / Governor / Health Minister / /

Product

dacarbazine / MSOffice1 / V600 / /

Technology

radiation / Consultation Decision Analytical Protocol / decision analytical protocol / gene expression / /

URL

http /

SocialTag